Pisa, Italy-based MMI (Medical Microinstruments, Inc.) has closed $110 million Series C financing led by Fidelity Management & Research Company to support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that will generate clinical evidence and enable indication expansion.

The Symani Surgical System is a first-of-its-kind robotic technology that uniquely addresses the scale and complexities of microsurgery and supermicrosurgery. By allowing surgeons to replicate the natural movements of the human hand at the micro scale, it can expand treatment options for patients in need of soft tissue, open surgical procedures, such as free flap reconstructions, lymphatic surgery, and trauma replantations. It is designed to help restore quality of life for more patients, accelerate the number of surgeons able to push the boundaries of complex procedures for delicate anatomy, and enable hospitals to expand their open surgical programs.

MMI projects the market for eligible robotic microsurgical procedures will grow from 3 million to 22 million annually by 2028, driven primarily by technological advancements and indication expansion.

To view the source version, please click HERE.

en_GBEnglish (UK)